Bristol Myers Squibb Updates Phase 3 YELLOWSTONE Trial Progress: Oral Zeposia (Ozanimod) Evaluation in Moderate to Severe Active Crohn’s Disease Patients
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program, which assesses Zeposia (ozanimod) in adult patients dealing with moderate…
Bristol Myers Squibb Broadens Health Equity Grant Programs for Enhanced Health Results
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations: Brazil, India, Thailand, and the United Kingdom. These new grants…
Bristol Myers Squibb Presents New Cardiovascular Findings at 2024 ACC Conference, Strengthening Evidence Base
Bristol Myers Squibb (NYSE: BMY) announced today the unveiling of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, in Atlanta, Georgia. Roland Chen, MD, Senior Vice President and Head of…
FDA Approves Roche’s Groundbreaking Molecular Test for Malaria Screening in Blood Donors
Roche, a leading healthcare company (SIX: RO, ROG; OTCQX: RHHBY), has announced today the approval by the U.S. Food and Drug Administration (FDA) for its cobas® Malaria test, designed for use on the cobas® 6800/8800 Systems. This milestone marks the…
EU Greenlights Merck’s KEYTRUDA® Combo for High-Risk NSCLC Treatment
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval allows its use in combination with platinum-containing chemotherapy as neoadjuvant…
Breakthrough FDA Approval: Merck’s WINREVAIR™ Revolutionizes PAH Treatment for Adults
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in the U.S., for injection in 45mg and 60mg doses. This…
AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused on developing novel oral therapeutics for patients with autoimmune diseases.…
Novo Nordisk’s Acquisition of Cardior Pharmaceuticals: Enhancing Cardiovascular Disease Pipeline
Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along with additional payments contingent upon the achievement of specific developmental…
Awiqli®: European Authorities Recommend Approval for Weekly Basal Insulin Icodec in Diabetes Treatment
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded name for once-weekly basal insulin icodec) for the treatment of…
Comprehensive Research on the Global Covid-19 Diagnostic Market for 2024: Executive and Consultant Guides Available – ResearchAndMarkets.com
The “Global Covid-19 Diagnostic Market Forecast by Technology, Product, Channel and Country with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. Amidst signs of the pandemic easing, Covid-19 continues to reshape markets, especially in the realm of respiratory diagnostics, where a…
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) has finalized its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for an estimated total equity value of about $4.3 billion. This strategic move enhances Gilead’s liver disease portfolio by incorporating CymaBay’s leading investigational product, seladelpar,…
GenSight Biologics Releases Comprehensive Financial Summary for Fiscal Year 2023
GenSight Biologics, a biopharmaceutical company listed on Euronext under the ticker symbol SIGHT and ISIN FR0013183985, eligible for PEA-PME, has disclosed its consolidated financial performance for the full year 2023. This report, approved by the Board of Directors on March…